Welcome to our dedicated page for Medline SEC filings (Ticker: MDLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Medline's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Medline's regulatory disclosures and financial reporting.
Medline Inc. reported Q2 2026 net sales of $7.7 billion, up 11.6% year over year, with Organic Sales growth of 11.5%. Gross margin improved to 28.8%. For the first six months, net sales reached $15.0 billion, up 11.1%, with Organic Sales up 10.8%.
Profitability was pressured by a $336 million loss from the Tracy, California distribution-center fire, higher operating expenses and tariff impacts. Q2 net income fell 58.3% to $139 million, while Adjusted EBITDA rose 13.4% to $1.1 billion. The company recognized $332 million of IEEPA tariff refunds and accrued $89 million of related customer repayments, for a net benefit of $243 million to net income and Adjusted EBITDA.
Operating cash flow for the first six months was $1.1 billion and Free Cash Flow was $920 million. Medline updated 2026 guidance, raising Organic Sales growth to 9.0%–10.0% but lowering Adjusted EBITDA to $3.3–$3.4 billion, citing inflation from the Middle East conflict, increased operational and quality investments, and retail channel softness.
Medline Inc. disclosed that its Chief Operating Officer, Stephen L. Miller, has notified the company of his decision to retire for health-related reasons. The retirement will be effective August 30, 2026. Medline has begun a search for a successor to the COO role.
Medline Inc. executive William J. Abrams reported a routine tax-related share disposition. On June 15, 2026, 1,308 shares of Class A Common Stock were withheld at $36.61 per share to cover his tax liability from vesting restricted stock units. This was not an open-market sale, and Abrams continues to hold 16,546 shares directly after the transaction.
Medline Inc. Chief Human Resources Officer Christopher P. Shryock reported a routine tax-withholding transaction involving company stock. On the vesting of restricted stock units, 872 shares of Class A Common Stock were withheld at a value of $36.61 per share to satisfy his tax liability, as noted in the footnote. After this non-market disposition for taxes, he directly holds 11,031 shares of Medline common stock.
Medline Inc.'s Chief Operating Officer Stephen L. Miller reported a routine tax-related share disposition. On the vesting of restricted stock units, 1,889 shares of Class A Common Stock were withheld at $36.61 per share to cover his tax liability. This was not an open-market sale. Following the withholding, Miller directly holds 23,899 shares, so he retains the vast majority of his equity position.
Medline Inc. Chief Legal Officer Alexander M. Liberman reported a routine tax-related share disposition. On the reported date, 872 shares of Class A Common Stock were withheld to cover his tax liability arising from the vesting of restricted stock units. After this withholding, he directly holds 11,031 shares of Medline Class A Common Stock. This event reflects a standard administrative step tied to equity compensation rather than an open-market sale.
Medline Inc. Chief Product Officer Amanda H. Laabs reported a routine tax-related share disposition. On the reported date, 1,889 shares of Class A Common Stock were withheld to cover her tax liability arising from the vesting of restricted stock units, at a value of $36.61 per share. After this withholding, she directly holds 23,899 shares of Medline common stock. This event reflects compensation-related tax settlement rather than an open-market stock sale.
Medline Inc. Chief Financial Officer Michael B. Drazin reported a tax-withholding disposition related to equity compensation. On the vesting of restricted stock units, 1,889 shares of Class A Common Stock were withheld at $36.61 per share to cover taxes, leaving him with 23,899 shares held directly.
Medline Inc. Chief Commercial Officer and 10% owner Douglas P. Golwas reported a mix of equity transactions involving Medline stock and partnership units. He exercised 100,000 Common Units of Medline Holdings, LP into 100,000 shares of Class A common stock, while an equivalent 100,000 shares of Class B common stock were automatically cancelled and returned to the issuer with no economic value exchanged.
Golwas then sold 38,034 Class A shares at a weighted average price of $37.05 per share and 61,966 Class A shares at a weighted average price of $36.60 per share, both under a pre-arranged Rule 10b5-1 trading plan. In a separate move tied to restricted stock unit vesting, 1,889 Class A shares were withheld to cover tax obligations. Following these transactions, he continues to hold significant direct Class A ownership and 365,864 Common Units of Medline Holdings, LP indirectly, each exchangeable one-for-one into Class A shares.
Medline Inc. director and Chief Executive Officer James M. Boyle reported a routine tax-related share disposition. The filing shows that 2,370 shares of Class A Common Stock were withheld at $36.61 per share to cover his tax liability linked to vesting restricted stock units. After this non-market transaction, Boyle directly holds 29,369 shares of Medline Inc. common stock.